Biovie's Bezisterum Shows Age Reversal and Alzheimer's Improvement in Phase Three Trials

Alzheimer's Drug Bezisterum: A Novel Epigenetic Approach

• 💡 Biovie Inc. presented phase three data for its Alzheimer's drug candidate, Bezisterum, at the World Aging and Rejuvenation Conference.
• 🧠 Unlike traditional treatments, Bezisterum employs an epigenetic approach to simultaneously modulate inflammation and rewire aging-related genes.

Groundbreaking Trial Results

• 📈 Patients treated with Bezisterum demonstrated biological age reversal, appearing up to four years younger based on DNA methylation clocks.
• 📊 The trial also showed statistically significant reductions in inflammatory and metabolic markers, including cholesterol and fasting glucose.
• 🧬 Gene-level changes associated with aging and cognition were also observed.

Potential Beyond Alzheimer's

• 🚀 Biovie is positioning Bezisterum not only as an Alzheimer's treatment but also as a potential therapy for slowing or reversing biological aging.
• ✅ The drug candidate boasts a favorable safety profile and a promising path forward, suggesting a significant impact on neurodegenerative care and longevity biotech.